COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

NEXT STORY
Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
PREV STORY
BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT®.TB Test

OXFORD, United Kingdom and MARLBOROUGH, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec ...

author_avatar
NASDAQ Market News

First half of the year with 1%1 growth at constant exchange rates, significant impact of COVID-19 pandemic

author_avatar
NASDAQ Market News

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

MELBOURNE, Australia, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage ...

author_avatar
NASDAQ Market News